Effect of Dextran sulfate sodium on the gut microbiome in a mouse model of Parkinson's Disease
The gut has not historically been thought a major contributor to Parkinson's Disease (PD), but many PD patients have digestive symptoms years before they exhibit neurological symptoms, and composition of the gut microbiome of PD patients differs from that of healthy controls. The gut microbiome plays also a role in the effects of PD-related environmental neurotoxins. Dextran sulfate sodium (DSS) primarily induces inflammation in the gut. In the current study, we rederived the A53T-L444P and A53T mouse lined originally generated by Dr. Nussbaum (Fishbein et al., 2014) to assess whether DSS has differential effects on behavioral performance in A53T and A53T-L444P mice and whether these effects are associated with alterations in the gut microbiome.